IL2 and renal cell carcinoma: A trial with stage I-II renal cell carcinoma patients revealed that IL-2 administered in the early morning (5:00–13:00) or late night (21:00–5:00) resulted in longer survival compared to afternoon administration (13:00–21:00) (9).